Original Data

Rev Diabet Stud, 2004, 1(2):80-88 DOI 10.1900/RDS.2004.1.80

Polyclonal Anti-T-Cell Therapy for Type 1 Diabetes Mellitus of Recent Onset

Frantisek Saudek, Tereza Havrdova, Petr Boucek, Ludmila Karasova, Peter Novota, Jelena Skibova

Diabetes Center, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 14021 Prague 4, Czech Republic.
Address correspondence to: Frantisek Saudek, e-mail: frantisek.saudek@medicon.cz

Keywords: Type 1 diabetes, immune intervention, antithymocyte globulin, ATG, insulin, C-peptide

Abstract

The destruction of pancreatic β-cells in type 1 diabetes mellitus is mediated by autoreactive T-lymphocyte clones. We initiated a prospective randomized controlled trial of polyclonal rabbit anti-T-cell globulin (ATG) in patients with type 1 diabetes within 4 weeks of diagnosis and with residual post-glucagon C-peptide levels still over 0.3 nmol/l. ATG was administered as an initial bolus of 9 mg/kg followed by 3 consecutive doses of 3 mg/kg. An interim analysis was performed to establish whether any significant changes in C-peptide production and insulin requirement had occurred that would justify the continuation of this pilot study. By May 2004, 11 subjects were assigned to treatment with ATG along with intensified insulin therapy and 6 to intensified insulin therapy with placebo, and were followed for a period of at least 6 months. During the first 12 months a significant difference in the insulin dose trends was found between the groups (p = 0.010) with a lower insulin dosage in the ATG group. There was also a difference in the glucagon stimulated C-peptide level trends of marginal significance (p = 0.068). Compared to values at screening, stimulated C-peptide levels significantly improved in the ATG group (p = 0.012) but not in the placebo group. Complete diabetes remission occurred in 2 patients in the ATG and in none of the placebo group. Glycosylated hemoglobin at 12 months tended to be lower in the ATG group (p = 0.088). Significant adverse effects of ATG treatment, mainly transient fever and moderate symptoms of serum sickness (7 and 6 subjects, respectively) were observed during the first month only. The interim analysis of this ongoing study suggests that short-term ATG therapy in type 1 diabetes of recent onset contributes to the preservation of residual C-peptide production and to lower insulin requirements in the first year following diagnosis.

Fulltext: HTML , PDF (358KB)


This article has been cited by other articles:

Immune-Directed Therapy for Type 1 Diabetes at the Clinical Level: The Immune Tolerance Network (ITN) Experience

Ehlers MR, Nepom GT

Rev Diabet Stud 2012. 9(4):359-371

Regulatory T-cells in Graves' orbitopathy: baseline findings and immunomodulation by anti-T lymphocyte globulin

Kahaly GJ, Shimony O, Gellman YN, Lytton SD, Eshkar-Sebban L, Rosenblum N, Refaeli E, Kassem S, Ilany J, Naor D

J Clin Endocrinol Metab 2011. 96(2):422-429

The potential utility of bone marrow or umbilical cord blood transplantation for the treatment of type I diabetes mellitus

Mabed M

Biol Blood Marrow Transplant 2011. 17(4):455-464

Stem cell-based therapies and immunomodulatory approaches in newly diagnosed type 1 diabetes

Couri CE, Voltarelli JC

Curr Stem Cell Res Ther 2011. 6(1):10-15

Immunotherapy of type 1 diabetes - how to rationally prioritize combination therapies in T1D

Boettler T, von Herrath M

Int Immunopharmacol 2010. 10(12):1491-1495

Efforts to prevent and halt autoimmune beta cell destruction

Haller MJ, Atkinson MA, Schatz DA

Endocrinol Metab Clin North Am 2010. 39(3):527-539

Immunotherapy of type 1 diabetes: where are we and where should we be going?

Luo X, Herold KC, Miller SD

Immunity 2010. 32(4):488-499

Stem cell therapy for type 1 diabetes mellitus

Aguayo-Mazzucato C, Bonner-Weir S

Nat Rev Endocrinol 2010. 6(3):139-148

Autologous hematopoietic stem cell transplantation for childhood autoimmune disease

Milanetti F, Abinun M, Voltarelli JC, Burt RK

Pediatr Clin North Am 2010. 57(1):239-271

Immune depletion with cellular mobilization imparts immunoregulation and reverses autoimmune diabetes in nonobese diabetic mice

Parker MJ, Xue S, Alexander JJ, Wasserfall CH, Campbell-Thompson ML, Battaglia M, Gregori S, Mathews CE, Song S, Troutt M, Eisenbeis S, Williams J, Schatz DA, Haller MJ, Atkinson MA

Diabetes 2009. 58(10):2277-2284

Immunotherapy for the prevention and treatment of type 1 diabetes: human trials and a look into the future

Rewers M, Gottlieb P

Diabetes Care 2009. 32(10):1769-1782

C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus

Couri CE, Oliveira MC, Stracieri AB, Moraes DA, Pieroni F, Barros GM, Madeira MI, Malmegrim KC, Foss-Freitas MC, Simões BP, Martinez EZ, Foss MC, Burt RK, Voltarelli JC

JAMA 2009. 301(15):1573-1579

Diabetes - adult stem cells as a future alternative therapy?

Ulicna M, Danisovic L, Danihel L, Vojtassak J

Bratisl Lek Listy 2009. 110(12):773-776

Engineered antibodies for type 1 diabetes

Hampe CS

Curr Opin Investig Drugs 2009. 10(4):336-345

Stem cell therapy for type 1 diabetes mellitus: a review of recent clinical trials

Couri CE, Voltarelli JC

Diabetol Metab Syndr 2009. 1(1):19

An update on preventive and regenerative therapies in diabetes mellitus

Reimann M, Bonifacio E, Solimena M, Schwarz PE, Ludwig B, Hanefeld M, Bornstein SR

Pharmacol Ther 2009. 121(3):317-331

Harnessing regulatory T cells for the therapy of lupus and other autoimmune diseases

Sharabi A, Mozes E

Immunother 2009. 1(3):385-401

Autologous stem cell transplantation for early type 1 diabetes mellitus

Couri CE, Voltarelli JC

Autoimmunity 2008. 41(8):666-672

Human regulatory T cells: role in autoimmune disease and therapeutic opportunities

Brusko TM, Putnam AL, Bluestone JA

Immunol Rev 2008. 223:371-390

Imaging the Beta-Cell Mass: Why and How

Saudek F, Brogren CH, Manohar S

Rev Diabet Stud 2008. 5(1):6-12

Beta-cell regeneration to treat Type 1 diabetes mellitus

Barra Couri CE, Foss-Freitas MC, Foss MC, Voltarelli JC

Expert Rev Endocr Metabol 2008. 3(1):51-60

Treatment of autoimmune disease with rabbit anti-T lymphocyte globulin: clinical efficacy and potential mechanisms of action

Lytton SD, Denton CP, Nutzenberger AM

Ann N Y Acad Sci 2007. 1110:285-296

Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus

Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simoes BP, Foss MC, Squiers E, Burt RK

JAMA 2007. 297(14):1568-1576